Deep Venous Thrombosis
88
5
8
47
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
11 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.4%
10 terminated out of 88 trials
82.5%
-4.0% vs benchmark
30%
26 trials in Phase 3/4
23%
11 of 47 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 47 completed trials
Clinical Trials (88)
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Bedside Bike Early Mobilization Program for Inpatients
The Protrieve PROTECTOR Study
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
Second Line Endovascular Treatment in Acute DVT
Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT
CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
Comparison of the Effects of Lower Limb Immobilisation With Cast and Orthosis
Effects of External Leg Compression Devices on Healing and Blood Clotting
Early Mobilization After Achilles Tendon Rupture
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
Screening for Cancer in Patients With Unprovoked VTE
Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology